Skip to results

Expected publication date

Expected publication date

Area of interest

Area of interest

Type (1 selected)

Type

Guidance programme (1 selected)

Guidance programme

Showing 251 to 260 of 320

Guidance, NICE advice and quality standards in development
TitleTypeExpected publication date
Rivogenlecleucel for treating haematological cancers in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1601]Technology appraisal guidanceTBC
Rivogenlecleucel for treating haematological non-malignant diseases in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1496]Technology appraisal guidanceTBC
Ropeginterferon alfa-2b for treating polycythaemia vera without symptomatic splenomegaly [ID1596]Technology appraisal guidanceTBC
Rozanolixizumab for treating antibody-positive generalised myasthenia gravis [ID5092]Technology appraisal guidanceTBC
Rucaparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy [ID5100]Technology appraisal guidance
Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer (Review of TA611) [ID4069]Technology appraisal guidance
Ruxolitinib for treating acute graft versus host disease refractory to corticosteroids in people aged 12 and over [ID6377]Technology appraisal guidanceTBC
Ruxolitinib for treating moderate to severe chronic graft-versus-host disease after an allogeneic stem cell transplant in people 28 days to 17 years [ID6427]Technology appraisal guidanceTBC
Ruxolitinib for treating non-segmental vitiligo in people 12 years and over [ID3998]Technology appraisal guidance
Sacituzumab govitecan for treating advanced non-small-cell lung cancer after platinum-based chemotherapy and a PD-1 or PD-L1 inhibitor [ID6375]Technology appraisal guidanceTBC

Results per page

  1. 10
  2. 25
  3. 50
  4. All